6/5/2023 0 Comments Meclizine dosage for vertigo![]() ![]() Strong CNS depressants should not be coadministered with blonanserin. Management: Use caution if coadministering blonanserin and CNS depressants dose reduction of the other CNS depressant may be required. Risk C: Monitor therapyīlonanserin: CNS Depressants may enhance the CNS depressant effect of Blonanserin. Betahistine may diminish the therapeutic effect of Antihistamines. Risk D: Consider therapy modificationīetahistine: Antihistamines may diminish the therapeutic effect of Betahistine. A histamine skin test may be used to assess persistent antihistaminic effects. Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. ![]() Risk X: Avoid combinationīenzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Risk C: Monitor therapyĪzelastine (Nasal): May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapyĪnticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents. Risk C: Monitor therapyĪmezinium: Antihistamines may enhance the stimulatory effect of Amezinium. Risk C: Monitor therapyĪmantadine: May enhance the anticholinergic effect of Anticholinergic Agents. Risk C: Monitor therapyĪlizapride: May enhance the CNS depressant effect of CNS Depressants. Risk X: Avoid combinationĪlcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapyĪclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.Īcetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers ” are NOT listed). Tartrazine: Some formulations may contain FD&C yellow #5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in susceptible individuals, particularly those with aspirin sensitivity.Phenylalanine: Some chewable tablets contain phenylalanine.Older adult: Use with caution in older adults may be more sensitive to adverse effects.CYP2D6 polymorphism: Large inter-individual variability in meclizine exposure may occur in patients with CYP2D6 phenotypes that result in poor, intermediate, extensive, or ultra-rapid metabolism monitor for adverse reactions and clinical effect accordingly.Renal impairment: Renal impairment may lead to drug accumulation (effects have not been evaluated) use with caution. ![]() ![]()
0 Comments
Leave a Reply. |